Attached files

file filename
EX-10.24 - EXECUTIVE EMPLOYMENT AGREEMENT - MOLL - Adamis Pharmaceuticals Corpex10-24.htm
EX-10.23 - EXECUTIVE EMPLOYMENT AGREEMENT - DANIELS - Adamis Pharmaceuticals Corpex10-23.htm
EX-10.20 - EXECUTIVE EMPLOYMENT AGREEMENT - MARGUGLIO - Adamis Pharmaceuticals Corpex10-20.htm
EX-10.21 - EXECUTIVE EMPLOYMENT AGREEMENT - HOPKINS - Adamis Pharmaceuticals Corpex10-21.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex31-1.htm
EX-10.19 - EXECUTIVE EMPLOYMENT AGREEMENT - CARLO - Adamis Pharmaceuticals Corpex10-19.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex32-1.htm
10-K - ANNUAL REPORT - Adamis Pharmaceuticals Corpadmp_10k-123115.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex31-2.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex32-2.htm

 

ADAMIS PHARMACEUTICALS CORPORATION 10-K

 

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Prospectus constituting a part of the Registration Statements on Form S-8 (Nos. 333-159229, 333-169106, 333-175383, 333-196435, and 333-201742), on Form S-1 (Nos. 333-190798, 333-192372, and 333- 192801), and on Form S-3 (Nos. 333-196976, 333-199454, 333-200447 and 333-209401) of our report dated March 23, 2016, (which includes an explanatory paragraph relating to the uncertainty of the Company’s ability to continue as a going concern) relating to the consolidated financial statements of Adamis Pharmaceuticals Corporation and Subsidiaries (the Company), as of and for the periods ended December 31, 2015 and December 31, 2014, which report is included in this Annual Report on Form 10-K.

 

/s/ MAYER HOFFMAN MCCANN P.C.

San Diego, California

March 23, 2016